{"nctId":"NCT04401293","briefTitle":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","startDateStruct":{"date":"2020-04-26","type":"ACTUAL"},"conditions":["Sars-CoV2","COVID"],"count":257,"armGroups":[{"label":"Full Dose LMWH anticoagulation therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Enoxaparin"]},{"label":"Prophylactic/Intermediate Dose LMWH or UFH therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prophylactic/Intermediate Dose Enoxaparin"]}],"interventions":[{"name":"Enoxaparin","otherNames":[]},{"name":"Prophylactic/Intermediate Dose Enoxaparin","otherNames":["Unfractionated heparin","dalteparin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.\n2. Understands and agrees to comply with planned study procedures.\n3. Male or non-pregnant female adult ≥18 years of age at time of enrollment.\n4. Subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation.\n5. Subjects with a positive COVID-19 diagnosis by nasal swab or serologic testing.\n6. Hospitalized with a requirement for supplemental oxygen.\n7. Have:\n\n   * Either a D- Dimer \\> 4.0 X ULN, OR\n   * Sepsis-induced coagulopathy (SIC) score of ≥4\n\nExclusion Criteria:\n\n1. Indications for therapeutic anticoagulation\n2. Absolute contraindication to anticoagulation including:\n\n   1. active bleeding,\n   2. recent (within 1 month) history of bleed,\n   3. dual (but not single) antiplatelet therapy,\n   4. active gastrointestinal and intracranial cancer,\n   5. a history of bronchiectasis or pulmonary cavitation,\n   6. Hepatic failure with a baseline INR \\> 1.5,\n   7. CrCl \\< 15ml/min,\n   8. a platelet count \\< 25,000,\n   9. a history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies,\n   10. contraindications to enoxaparin including a hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol,\n   11. pregnant female,\n   12. inability to give or designate to give informed consent,\n   13. participation in another blinded trial of investigational drug therapy for COVID-19","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days.","description":"Risk of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Day 30 ± 2 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Bleeding","description":"Risk of major bleeding defined using the International Society of Thrombosis and Haemostasis (ISTH) criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Hospital Day 10 + 4","description":"The composite of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Hospital Day 10 + 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sepsis-induced Coagulopathy (SIC) Score","description":"Sepsis-induced coagulopathy (SIC) score predicts likelihood of sepsis-induced coagulopathy based on ISTH guidelines.\n\nThe score uses the following domains:\n\n* Platelets, K/uL (thousands per microliter)\n* INR (International Normalized Ratio)\n* D-Dimer Level\n* Fibrinogen\n\nPlatelet count \\> 100 cells x 10\\^9/L is 0 points, platelet count 50 to 100 cells x 10\\^9/L is 1 point and Platelet count \\< 50 cells x 10\\^9/L is 2 points. INR \\< 1.3 is 0 points, INR 1.3 to 1.7 is 1 point and INR \\> 1.7 is 2 points. D-Dimer level \\< 400 ng/mL is 0 points, D-Dimer level 400-4000 ng/mL is 2 points and D-Dimer level \\> 4000 ng/mL is 3 points. Fibrinogen level \\> 100 mg/dL is 0 points and fibrinogen level \\< 100 mg/dL is 1 point.\n\nCalculated (SIC) scores yields a possible 0 to 6 points, where ≥4 predicts higher mortality rates within 30 days and greater risk of pulmonary embolism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"0.73"},{"groupId":"OG001","value":"2.31","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Progression to Acute Respiratory Distress Syndrome (ARDS)","description":"Progression to Acute Respiratory Distress Syndrome (ARDS) based on monitoring of patient conditions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Need for Intubation","description":"Need for Intubation will be based on monitoring of patient conditions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Re-hospitalization","description":"Need for Re-hospitalization will be based on monitoring of patient conditions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":[]}}}